Krystal Biotech, Inc. (NASDAQ:KRYS) Receives $340.56 Average PT from Analysts

Posted by on Jul 8th, 2026

Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the twelve brokerages that are covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $340.5556.

A number of research analysts have issued reports on the company. HC Wainwright upped their price objective on Krystal Biotech from $310.00 to $361.00 and gave the company a “buy” rating in a research note on Tuesday, June 16th. Evercore reiterated an “outperform” rating and set a $300.00 target price on shares of Krystal Biotech in a research note on Tuesday, May 5th. Wall Street Zen downgraded shares of Krystal Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Citigroup increased their price target on shares of Krystal Biotech from $371.00 to $378.00 and gave the company a “buy” rating in a research report on Tuesday, May 5th. Finally, Weiss Ratings cut shares of Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, July 1st.

Get Our Latest Research Report on Krystal Biotech

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $308.11, for a total value of $7,702,750.00. Following the completion of the sale, the insider directly owned 1,378,155 shares in the company, valued at approximately $424,623,337.05. This trade represents a 1.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Charles Thomas sold 1,000 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $347.27, for a total transaction of $347,270.00. Following the transaction, the executive vice president owned 1,000 shares in the company, valued at approximately $347,270. This trade represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 26,642 shares of company stock worth $8,243,923 over the last ninety days. 13.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Krystal Biotech

Several large investors have recently added to or reduced their stakes in the company. Sound Income Strategies LLC lifted its stake in shares of Krystal Biotech by 1,270.0% during the 4th quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock valued at $34,000 after buying an additional 127 shares in the last quarter. Western Wealth Management LLC purchased a new position in Krystal Biotech during the 1st quarter valued at approximately $34,000. Greenline Wealth Management LLC bought a new stake in Krystal Biotech in the fourth quarter worth $34,000. Danske Bank A S bought a new stake in shares of Krystal Biotech in the 3rd quarter worth about $35,000. Finally, UMB Bank n.a. raised its position in Krystal Biotech by 34.6% during the fourth quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after purchasing an additional 37 shares during the period. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Stock Down 1.6%

Krystal Biotech stock opened at $368.60 on Friday. Krystal Biotech has a 52 week low of $130.50 and a 52 week high of $382.54. The company’s 50 day moving average price is $318.94 and its two-hundred day moving average price is $283.56. The stock has a market cap of $10.87 billion, a P/E ratio of 49.28 and a beta of 0.50.

Krystal Biotech (NASDAQ:KRYS – Get Free Report) last released its earnings results on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.45 by $0.38. The company had revenue of $116.36 million during the quarter, compared to analyst estimates of $112.11 million. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%. On average, equities analysts anticipate that Krystal Biotech will post 7.66 EPS for the current year.

Krystal Biotech Company Profile

(Get Free Report)

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.

Featured Articles

Analyst Recommendations for Krystal Biotech (NASDAQ:KRYS)

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.